Related Experiment Video
Updated: Jun 18, 2025

A Method for Evaluating the Reinforcing Properties of Ethanol in Rats without Water Deprivation, Saccharin Fading or Extended Access Training
Published on: January 29, 2017
Buprenorphine/naloxone - one formulation that doesn't fit all: a case report
Hannan M Braun1,2, Jessica L Taylor3,4, Sarah Axelrath5
1Division of General Internal Medicine, Denver Health and Hospital Authority, 301 W 6th Ave, Denver, 80204, CO, USA. Hannan.Braun@dhha.org.
Sublingual buprenorphine/naloxone is used for opioid use disorder, but naloxone can cause side effects in some patients. Switching to buprenorphine alone may resolve these adverse effects, improving treatment.
Area of Science:
- Pharmacology
- Addiction Medicine
Background:
- Sublingual buprenorphine/naloxone is a common treatment for opioid use disorder.
- Naloxone is included to deter misuse, but its absorption and effects may vary.
- Patient and provider understanding of naloxone's role can be limited.
Observation:
- A patient experienced adverse effects from sublingual buprenorphine/naloxone.
- These side effects resolved upon switching to sublingual buprenorphine monoproduct.
Findings:
- Naloxone is detectable in most patients on sublingual buprenorphine/naloxone.
- A subset of patients experience adverse effects attributable to naloxone.
- Misunderstanding of naloxone can impact patient-provider trust.
Implications:
- Clinicians should consider buprenorphine monoproduct for patients experiencing adverse effects.
- Individualized treatment approaches are crucial for managing opioid use disorder.
- Further research into naloxone's variable effects in sublingual formulations is warranted.
Related Concept Videos
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Opioid Receptors: Overview
Opioid Analgesics: Morphine and Other Natural Cogeners
Analgesia and Pain Management
Drug Delivery: Enteral Route
Drug Abuse and Addiction: Pharmacological Phenomena

